Biocon’s ALZUMAb (itolizumab) Receives the DCGI’s Approval for Emergency Use to Treat Patients with Moderate to Severe COVID-19
Biocon Biologics Signs a In-License Agreement with Just – Evotec Biologics for its Biosimilar Assets
Shots:
- The approval is based on the positive outcomes of a clinical trial assessing Itolizumab for its safety and efficacy in preventing CRS in moderate to severe ARDS patients due to COVID-19 at multiple hospitals in Mumbai and New Delhi
- The study met its 1EP with a reduction in mortality rates and other 2EPs for efficacy and biomarkers were also achieved
- ALZUMAb (itolizumab, 25mg/5mL) is an anti-CD6 IgG1 mAb launched for the treatment of chronic plaque psoriasis in India in 2013, manufactured and formulated IV injection at Biocon’s bio-manufacturing facility at Biocon Park, Bengaluru
Click here to read full press release/ article | Ref: Biocon | Image: Behnace